bioRxiv · 10.64898/2026.11.09.765291
Biochemical reassessment of the activation of PANK1 by SGLT2 inhibitors
Abstract
Although SGLT2 inhibitors (SGLT2i) show cardiovascular benefits in addition to glycemic control, their molecular target for cardiovascular effect remains unclear. A recent study reported that two SGLT2i, empagliflozin and dapagliflozin, directly activate pantothenate kinase 1 (PANK1), which mediate their cardioprotective effect. PANK1 phosphorylates pantothenate with ATP to yield 4'-phosphopantothenate and ADP, representing the rate-limiting enzyme of coenzyme A (CoA) biosynthesis. We therefore reassessed this claim using purified recombinant human PANK1. The malachite green assay detected free inorganic phosphate (Pi) but neither ADP nor 4'-phosphopantothenate and its signals do not reflect PANK1 activity. In the ADP-Glo assay, empagliflozin and dapagliflozin did not stimulate PANK1 under either basal conditions or acetyl-CoA feedback inhibition, while the activator PZ-2891 enhanced the activity of PANK1. These results show that SGLT2i do not directly activate PANK1, challenging the proposed PANK1-dependent cardioprotection mechanism.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Guo, Z., Zang, J., Chen, L.. 2026-11-13. Biochemical reassessment of the activation of PANK1 by SGLT2 inhibitors. https://doi.org/10.64898/2026.11.09.765291
Cite the original work for its findings. Save a collection to share your selection of sources.